Outcomes and prognostic factors in nodular melanomas.

[1]  I. Osman,et al.  Superficial spreading and nodular melanoma are distinct biological entities: a challenge to the linear progression model , 2012, Melanoma research.

[2]  M. Weinstock,et al.  The contribution of nodular subtype to melanoma mortality in the United States, 1978 to 2007. , 2012, Archives of dermatology.

[3]  A. Liossi,et al.  Immunohistochemical expression of VEGF, HIF1-a, and PlGF in malignant melanomas and dysplastic nevi , 2011, Melanoma research.

[4]  R. Scolyer,et al.  Factors Predicting Recurrence and Survival in Sentinel Lymph Node-Positive Melanoma Patients , 2011, Annals of surgery.

[5]  J. Choi,et al.  Frequencies of BRAF and NRAS mutations are different in histological types and sites of origin of cutaneous melanoma: a meta‐analysis , 2011, The British journal of dermatology.

[6]  C. Berking,et al.  Prognostic factors associated with sentinel lymph node positivity and effect of sentinel status on survival: an analysis of 1049 patients with cutaneous melanoma , 2010, Melanoma research.

[7]  A. Stromberg,et al.  The Prognostic Significance of Nonsentinel Lymph Node Metastasis in Melanoma , 2010, Annals of Surgical Oncology.

[8]  K. Dabbs,et al.  Predictors of sentinel lymph node metastasis in melanoma. , 2010, Canadian journal of surgery. Journal canadien de chirurgie.

[9]  Daniel B. Shin,et al.  Characteristics associated with early and late melanoma metastases , 2006, Cancer.

[10]  Jeffrey E Gershenwald,et al.  Final version of 2009 AJCC melanoma staging and classification. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  A. Chang,et al.  Prognostic Significance of a Positive Nonsentinel Lymph Node in Cutaneous Melanoma , 2009, Annals of Surgical Oncology.

[12]  M. Mazumdar,et al.  Changes in the presentation of nodular and superficial spreading melanomas over 35 years , 2008, Cancer.

[13]  M. Ross,et al.  Final results of the Sunbelt Melanoma Trial , 2008 .

[14]  M. Gönen,et al.  Positive Nonsentinel Node Status Predicts Mortality in Patients with Cutaneous Melanoma , 2008, Annals of Surgical Oncology.

[15]  S. Ariyan,et al.  Gender-Related Differences in Outcome for Melanoma Patients , 2006, Annals of surgery.

[16]  Gary Lyman,et al.  Age as a prognostic factor in the malignant melanoma population , 1994, Annals of Surgical Oncology.

[17]  K. Hemminki,et al.  BRAF and NRAS mutations are frequent in nodular melanoma but are not associated with tumor cell proliferation or patient survival. , 2005, The Journal of investigative dermatology.

[18]  Donald R. Miller,et al.  Early detection of thick melanomas in the United States: beware of the nodular subtype. , 2005, Archives of dermatology.

[19]  C. Ingvar,et al.  Invasive cutaneous malignant melanoma in Sweden, 1990–1999 , 2004, Cancer.

[20]  M. Ross,et al.  Lessons learned from the Sunbelt Melanoma Trial , 2004, Journal of surgical oncology.

[21]  A. Stromberg,et al.  Correlation Between Prognostic Factors and Increasing Age in Melanoma , 2004, Annals of Surgical Oncology.

[22]  G. Giles,et al.  Nodular type and older age as the most significant associations of thick melanoma in Victoria, Australia. , 2002, Archives of dermatology.

[23]  M. Ross,et al.  Factors that predict the presence of sentinel lymph node metastasis in patients with melanoma. , 2001, Surgery.

[24]  P. V. van Diest,et al.  The sentinel lymph node status is an important factor for predicting clinical outcome in patients with Stage I or II cutaneous melanoma , 2001, Cancer.

[25]  W. Clark,et al.  The classification of malignant melanoma and its histologic reporting , 1973, Cancer.